HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience.

AbstractBACKGROUND:
Iron chelation therapy is an important component in the management of patients with β-thalassemia.
METHODS:
The study included 87 children with transfusion-dependent β-thalassemia aged 2-17 years (mean, 8.2 ± 4.1 years), 49 (56%) of whom were male. The patients received deferasirox 9-40 mg/kg per day as a single dose for 36 months. They were clinically and laboratory monitored.
RESULTS:
The treatment was generally well tolerated. Drug-related adverse events, including abdominal pain (14.9%) and nausea (5.8%), high alanine aminotransferase more than double the upper limit of normal (5.8%), and non-progressive rise in serum creatinine (2.3%), were generally mild to moderate, transient, and reduced in frequency over time. Two patients discontinued treatment due to severe abdominal pain and nausea. Mean deferasirox dose was calculated as 21.2 ± 8.6, 23.7 ± 8.1, 30.7 ± 8.2 and 32.4 ± 7.6 mg/kg per day at 0, 12, 24 and 36 months, respectively. Mean (median) serum ferritin level was found to increase progressively during the first 22 months of treatment, from 3.161 ± 1.683 ng/mL (2.760 ng/mL) to 3.679 ± 1.997 ng/mL (3.071 ng/mL; P < 0.001) and then decreased gradually to 2.907 ± 1.436 ng/mL (2.670 ng/mL; P = 0.023) at 36 months.
CONCLUSION:
Deferasirox is safe and well tolerated; doses 21-24 mg/kg per day were not able to maintain stable iron balance, but ≥ 30 mg/kg per day was able to reduce iron in regularly transfused pediatric patients.
AuthorsAli Aycicek, Ahmet Koc, Mahmut Abuhandan
JournalPediatrics international : official journal of the Japan Pediatric Society (Pediatr Int) Vol. 56 Issue 4 Pg. 530-3 (Aug 2014) ISSN: 1442-200X [Electronic] Australia
PMID24612039 (Publication Type: Clinical Trial, Journal Article)
Copyright© 2014 Japan Pediatric Society.
Chemical References
  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Deferasirox
Topics
  • Adolescent
  • Benzoates (therapeutic use)
  • Child
  • Child, Preschool
  • Deferasirox
  • Female
  • Humans
  • Iron Chelating Agents (therapeutic use)
  • Male
  • Treatment Outcome
  • Triazoles (therapeutic use)
  • beta-Thalassemia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: